News Takeda's narcolepsy programme gets back on track Takeda will move quickly ahead with regulatory filings for oveporexton as a treatment for narcolepsy after a pair of phase 3 wins.
News NICE relents on Takeda colorectal cancer drug Fruzaqla Colorectal cancer patients could soon have access via the NHS to a targeted oral drug that can give them more precious time with their loved ones.
News MSD aims to plug dengue fever vaccine gap in US MSD is preparing to take on Takeda in the dengue fever vaccine market, moving its V181 candidate into phase 3.
News Takeda scores with polycythemia vera drug in phase 3 trial A phase 3 win suggests Takeda's $300m wager on Protagonist's rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off.
News Takeda CEO succession confirmed as Weber plans retirement Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker.
News Takeda backs biomarker trial for Crohn's prevention The INTERCEPT trial aims to validate biomarkers that could identify people at risk of Crohn's and see if treatment can prevent symptoms developing.
